Epygenix Therapeutics, a clinical-stage biopharmaceutical company founded on UCSF researcher Scott Baraban's work and focused on rare and intractable genetic epilepsy, announced today that Health Canada issued a "No Objection Letter" (NOL) to proceed with the ELEGANSE trial for the treatment of Lennox-Gastaut Syndrome (LGS) with EPX-100 (Clemizole HCl). This ELEGANSE trial will evaluate the efficacy and safety of EPX-100 with patients suffering from LGS.
